TY - JOUR
T1 - Health-related Quality of Life of Patients with Non-intra-abdominal Desmoid-type Fibromatosis during Active Surveillance
T2 - Results of a Prospective Observational Study
AU - Schut, Anne Rose W.
AU - Timbergen, Milea J.M.
AU - Nasserinejad, Kazem
AU - Dutch Grafiti Group
AU - Van Dalen, Thijs
AU - Van Houdt, Winan J.
AU - Bonenkamp, Johannes J.
AU - Sleijfer, Stefan
AU - Grünhagen, Dirk J.
AU - Verhoef, Cornelis
AU - Husson, Olga
AU - Schut, Anne Rose W.
AU - Timbergen, Milea J.M.
AU - Van Broekhoven, Danique L.M.
AU - Van Houdt, Winan J.
AU - Van Coevorden, Frits
AU - Van Der Hage, Jos A.
AU - Dijkstra, Sander D.S.
AU - Bonenkamp, Johannes J.
AU - Been, Lukas B.
AU - Van Ginkel, Robert J.
AU - Bemelmans, Marc H.A.
N1 - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - OBJECTIVE: To examine the impact of an active surveillance (AS) approach on health-related quality of life (HRQoL) of patients with desmoid-type fibromatosis (DTF).SUMMARY BACKGROUND DATA: AS is recommended as initial approach in DTF patients. AS might however negatively affect HRQoL due to physical symptoms or stress and anxiety.METHODS: In a prospective observational study, the GRAFITI trial (NTR4714), DTF patients were followed during an initial AS approach for three years. HRQoL was assessed by the EORTC QLQ-C30 at baseline, 6, 12 and 24-month follow-up. Patients who completed questionnaires at≥1 time point were included in this analysis of the secondary endpoint. A multivariable linear mixed-effects model with random intercept was conducted to assess trends of HRQoL scores over time and to explore the effect of treatment strategy on HRQoL.RESULTS:All 105 patients enrolled in the GRAFITI trial were eligible for the HRQoL analyses. During 24-month follow-up, 75 patients (71%) continued AS and 30 patients (29%) started an active treatment (AT). DTF patients who continued AS demonstrated relatively stable HRQoL scores during follow-up. HRQoL scores of patients who started AT worsened compared to patients who continued AS, although no significant changes in HRQoL score over time were found in the mixed-model analyses. Overall, DTF patients who started AT scored significantly worse on pain (β=10.08, P=0.039) compared to patients who continued AS.CONCLUSIONS: An initial AS approach did not impair HRQoL of DTF patients who continued AS over time, therefore providing further support for AS as the frontline approach in DTF patients. Longitudinal assessment of HRQoL should be part of clinical follow-up to identify patients who may need a change in treatment strategy.
AB - OBJECTIVE: To examine the impact of an active surveillance (AS) approach on health-related quality of life (HRQoL) of patients with desmoid-type fibromatosis (DTF).SUMMARY BACKGROUND DATA: AS is recommended as initial approach in DTF patients. AS might however negatively affect HRQoL due to physical symptoms or stress and anxiety.METHODS: In a prospective observational study, the GRAFITI trial (NTR4714), DTF patients were followed during an initial AS approach for three years. HRQoL was assessed by the EORTC QLQ-C30 at baseline, 6, 12 and 24-month follow-up. Patients who completed questionnaires at≥1 time point were included in this analysis of the secondary endpoint. A multivariable linear mixed-effects model with random intercept was conducted to assess trends of HRQoL scores over time and to explore the effect of treatment strategy on HRQoL.RESULTS:All 105 patients enrolled in the GRAFITI trial were eligible for the HRQoL analyses. During 24-month follow-up, 75 patients (71%) continued AS and 30 patients (29%) started an active treatment (AT). DTF patients who continued AS demonstrated relatively stable HRQoL scores during follow-up. HRQoL scores of patients who started AT worsened compared to patients who continued AS, although no significant changes in HRQoL score over time were found in the mixed-model analyses. Overall, DTF patients who started AT scored significantly worse on pain (β=10.08, P=0.039) compared to patients who continued AS.CONCLUSIONS: An initial AS approach did not impair HRQoL of DTF patients who continued AS over time, therefore providing further support for AS as the frontline approach in DTF patients. Longitudinal assessment of HRQoL should be part of clinical follow-up to identify patients who may need a change in treatment strategy.
UR - http://www.scopus.com/inward/record.url?scp=85159608024&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000005795
DO - 10.1097/SLA.0000000000005795
M3 - Article
C2 - 36727954
SN - 0003-4932
VL - 277
SP - 877
EP - 883
JO - Annals of Surgery
JF - Annals of Surgery
IS - 6
ER -